Psychedelics News

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

LONDON & NEW YORK, September 08, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced…

Psilocybin as a treatment for repetitive mild head injury: evidence from neuroradiology and molecular biology

This rat study investigated psilocybin after repetitive mild head injury and reported changes in brain swelling, vascular reactivity, connectivity and molecular markers associated with injury and plasticity. These neu...

Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD

This exploratory secondary analysis (n=27) found that stronger mystical experiences during psilocybin sessions were associated with lower OCD symptom severity one and 12 weeks later. Challenging experiences did not pr...

The American Legion adopted a resolution supporting psychedelic therapies and related research for veterans and service members with PTSD, depression or traumatic brain injury.

At its 107th National Convention in Louisville, Kentucky, The American Legion backed S.4220, the Veterans Health Administration’s Novel Therapeutics Preparedness Act. The bipartisan bill would create a VHA office to c...

Fisher Clinical Services, Inc. has applied to the Drug Enforcement Administration to register as an importer of basic classes of controlled substances.

The application was published by the Drug Enforcement Administration on 8 September 2026 and is open for public comment until 8 October 2026. The notice does not identify the controlled substances involved in the prov...

Irvine Labs, Inc. applied to the Drug Enforcement Administration to register as a bulk manufacturer of basic classes of controlled substances.

The Drug Enforcement Administration published the application on 8 September 2026. The notice opened a comment period ending 9 November 2026 and directs readers to supplementary information for details of the substanc...

Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD

This exploratory secondary analysis (n=27) found that stronger mystical experiences during psilocybin sessions were associated with lower OCD symptom severity one and 12 weeks later. Challenging experiences did not pr...

The FDA appointed permanent leaders for drugs, vaccines and biologics, and tobacco, naming Dr Michael Davis to oversee drug reviews including upcoming psychedelic therapies.

The Trump administration filled four senior FDA roles after months of turnover. Dr Michael Davis will lead the Center for Drug Evaluation and Research and oversee reviews of psychedelic drugs being studied for psychia...

Psilocybin as a treatment for repetitive mild head injury: evidence from neuroradiology and molecular biology

This rat study investigated psilocybin after repetitive mild head injury and reported changes in brain swelling, vascular reactivity, connectivity and molecular markers associated with injury and plasticity. These neu...

Ambio Life Sciences has published Ibogaine and the Bicameral Mind, a book by CEO and co-founder Jonathan Dickinson covering ibogaine’s pharmacology, history and clinical use.

The book was released on 8 September 2026 by Inner Traditions/Park Street Press. It presents ibogaine’s proposed “bicameral state” and examines its potential neuroregenerative applications for mild traumatic brain inj...

The International Legal Architecture for Ayahuasca

A new publication from ICEERS’ legal defense program maps the treaties, case law, and strategies that protect ayahuasca practices worldwide.

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Those Trump-Shaped Ecstasy Pills Actually Aren’t Ecstasy At All

PLUS, Amsterdam's last shroom shop, the legality of clinical ketamine, and Eliza Dushku as a psychedelic therapist. [...] Read More... The post Those Trump-Shaped Ecstasy Pills Actually Aren’t Ecstasy At All appeared ...

Temporal structure of psychedelic EEG: statistical unit, dose, and receptor mechanism in multi-scale dynamics

This preprint reanalysed public EEG datasets for psilocybin microdosing (n=31), ketamine (n=8) and DMT (n=6). Analyses treating participants as the statistical unit found no significant microdose effect, while both ke...

Metabolic Burden and Response to Repeated Intranasal Esketamine in Treatment-Resistant Depression: A Longitudinal Multidomain Biomarker Study

This observational preprint (n=30) followed people with treatment-resistant depression through eight intranasal esketamine treatments. Higher baseline metabolic burden was associated with greater improvement in depres...